PremiumThe FlyUnusually active option classes on open April 30th Merck price target lowered to $108 from $115 at Guggenheim Merck & Co. (MRK) Looks to New Cholesterol Drug as Keytruda Expiration Looms PremiumThe FlyMerck price target lowered to $100 from $115 at HSBC Merck & Co.’s Strategic Resilience and Growth Potential Amidst Macroeconomic Challenges Merck’s Earnings Call: Growth Potential and Challenges PremiumRatingsMerck & Co. Hold Rating: Gardasil Challenges and Keytruda Exclusivity Concerns Weigh on Market Performance Merck & Co. Rated ‘Buy’ by Analyst Tim Anderson for Growth Potential and Undervaluation Merck Reports Mixed Q1 2025 Financial Results 
